High-risk myeloma: a gene expression based risk-stratification model for newly diagnosed multiple myeloma treated with high-dose therapy is predictive of outcome in relapsed disease treated with single-agent bortezomib or high-dose dexamethasone.

To the editor: We recently described a tumor gene expression model capable of identifying multiple myeloma (MM) patients at high risk for short survival after high-dose therapy (HDT) that is also independent of standard high-risk variables.[1][1] This model was also recently shown to be able to

[1]  Yongsheng Huang,et al.  A validated gene expression model of high-risk multiple myeloma is defined by deregulated expression of genes mapping to chromosome 1. , 2006, Blood.

[2]  P. L. Bergsagel,et al.  Translocation t(4;14) retains prognostic significance even in the setting of high-risk molecular signature , 2008, Leukemia.

[3]  K. Koike,et al.  Spontaneous improvement of hematologic abnormalities in patients having juvenile myelomonocytic leukemia with specific RAS mutations. , 2007, Blood.

[4]  J. Downing,et al.  Gene Expression Profiling of Pediatric Acute Myelogenous Leukemia Materials and Methods , 2022 .

[5]  E. Lander,et al.  Gene expression signatures define novel oncogenic pathways in T cell acute lymphoblastic leukemia. , 2002, Cancer cell.

[6]  M. Woodruff,et al.  Immune Response , 1969, Nature.

[7]  E. Lanino,et al.  Hematopoietic stem cell transplantation (HSCT) in children with juvenile myelomonocytic leukemia (JMML): results of the EWOG-MDS/EBMT trial. , 2005, Blood.

[8]  Hartmut Goldschmidt,et al.  Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. , 2005, The New England journal of medicine.

[9]  J. Okamura,et al.  Allogeneic hematopoietic stem cell transplantation for 27 children with juvenile myelomonocytic leukemia diagnosed based on the criteria of the International JMML Working Group , 2002, Leukemia.

[10]  Anthony Boral,et al.  Gene expression profiling and correlation with outcome in clinical trials of the proteasome inhibitor bortezomib. , 2006, Blood.

[11]  L. Staudt,et al.  Signatures of the immune response. , 2001, Immunity.

[12]  J. Harbott,et al.  Chronic myelomonocytic leukemia in childhood: a retrospective analysis of 110 cases. European Working Group on Myelodysplastic Syndromes in Childhood (EWOG-MDS) , 1997, Blood.